

Hikma announces exclusive agreement with Scieure Pharma for niche injectable anti-viral medicine

London, 3 January 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement between its wholly-owned subsidiary Hikma Pharmaceuticals International Limited and Beijing Scieure Pharmaceutical Co., Ltd (Scieure), a leading Chinese company that researches, develops and manufactures high-quality pharmaceutical products for global markets.

The agreement provides Hikma with exclusive rights to sell one of Scieure's niche injectable anti-viral medicines across the US for a minimum of eight years, with an option to extend this partnership for an additional two years. Scieure expects to file this product for approval with the US Food and Drug Administration in early 2019.

"We are thrilled to partner with Scieure, an innovative and vertically integrated company capable of producing high-quality products across the pharmaceutical spectrum from API to finished doses," said Daniel Motto, Hikma's Executive Vice President of Commercial and Business Development. "Our partnership with Scieure is another example of how Hikma is continuing to expand its pipeline, targeting both niche products and high-volume opportunities, in order to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals."

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal
VP Corporate Strategy and Investor Relations

+44 20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com

Steven Weiss
Senior Director, Communications and Public Affair

+1 732 720 2830/ +1 732 788 8279
sweiss@hikma.com

FTI Consulting

Ben Atwell/Brett Pollard

+44 20 3727 1000

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

About Scieure

Beijing Scieure Pharmaceutical Co., Ltd (Scieure), is a leading China-based multi-national specialty pharmaceutical company which focuses on researching, developing and manufacturing high-barrier and complex medicines. Scieure's fully-integrated capabilities include research and development, API production, manufacturing and commercialization, in addition to strong clinical and regulatory experience. The company operates in Asia, Europe and North America, and maintains US-based business offices and a research and development laboratory in Monmouth Junction, NJ (Scieure Laboratories, LLC).